Here is the design of a clinical trial:

Official Title: Danish Study of Non-Invasive Diagnostic Testing in Coronary Artery Disease 3

Included conditions:
- Angina Pectoris
- Atherosclerosis
- Coronary Artery Disease
- Myocardial Ischemia

Study Armgroups:
- {'label': 'Cohort', 'description': 'Participants consenting to the study will undergo:\n\na1) An interview a2) Blood samples withdrawals a3) ECG a4) Non-enhanced CT a5) CCTA a6) Follow-up for \\> 10 years\n\nPatients with suspicion of coronary stenosis detected by CCTA will after undergo:\n\nb1) Rb PET b2) 15O-water PET b3) Invasive coronary angiography with 3 vessel measurement of fractional flow reserve (FFR), coronary flow reserve (CFR) and index of microvascular resistance (IMR)', 'interventionNames': ['Diagnostic Test: Head to head comparison: Rubidium vs 15O-water PET']}

Interventions:
- {'type': 'DIAGNOSTIC_TEST', 'name': 'Head to head comparison: Rubidium vs 15O-water PET', 'description': 'Head to head comparison with invasive FFR as reference. Adjustment for abnormal microcirculation', 'armGroupLabels': ['Cohort']}

Primary Outcomes:
- {'measure': 'Diagnostic accuracy of Rb PET and 15-O PET', 'description': 'Head-to-head comparison using ICA-FFR as reference standard stratified for CFR', 'timeFrame': 'ICA: 4 weeks after inclusion'}

Please estimate the sample size based on the assumption: 
Minimum of 8% absolute precision on both sides for the expected sensitivity and specificity.
Sample size
          Based on the Dan-NICAD 1 and 2 trials, we expect that approximately 1000 patients are needed to be included and undergo coronary CTA. Following coronary CTA, we expect that 250 (25%) patients in whom coronary stenosis cannot be ruled out are eligible for continuing to the perfusion examinations and ICA part of the study. We expect 80% to complete both 82Rb-PET and 15O-water-PET and undergo ICA examination. By including 1000 patients, we are able to evaluate the predictive validity parameters (sensitivity, specificity, positive and negative predictive values) with a minimum of 8% absolute precision on both sides for the expected sensitivity (80%) and specificity (80%) for both 82Rb-PET and 15O-water-PET at a disease prevalence of 50% at ICA-FFR.